New Insights into Effects of Dual RAAS Blockade in CKD

Restricted access

In patients with chronic kidney disease (CKD), the acute response to a potassium challenge may predict chronic changes in potassium level while receiving dual renin-angiotensin-aldosterone (RAAS) blockade, reports a study in Hypertension.

The randomized, crossover trial included 18 patients with hypertension and CKD with a glomerular filtration rate of 25 to 65 mL/min. In random order, the patients received four weeks of treatment with dual RAAS blockade, consisting of lisinopril 40 mg/dL and spironolactone 25 mg/dL, and four weeks of placebo. After each treatment, dynamic renal potassium excretion and serum potassium were assessed after a 35 mmol oral

Save